Toshiba Appoints Rance M. Poehler as President & Chief Executive Officer for Retail Solutions Business
16.11.2020 19:00:00 EET | Business Wire | Press release
Toshiba Global Commerce Solutions today announced Rance M. Poehler is joining the company as its new President and Chief Executive Officer effective November 16, 2020. Poehler has more than 25 years of experience building and expanding business-to-business organizations in unique vertical markets including retail where he has led the development of end-to-end solutions for general retail, quick-service restaurant, hospitality, and other segments. In his role, he will be responsible for leading the company’s continued transformation as a trusted retail commerce solutions leader for its large and growing customer and partner community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005083/en/
Rance M. Poehle, President & CEO, Toshiba Global Commerce Solutions (Photo: Business Wire)
Poehler replaces Scott Maccabe who had been appointed President & CEO since 2015. Maccabe is retiring from his role as President & CEO at Toshiba Global Commerce Solutions, while he remains in this capacity at Toshiba America Business Solutions. Poehler takes over effective immediately and will work closely with Maccabe to ensure a full and seamless transition of duties. We thank Scott Maccabe for his commitment, strong leadership and many contributions to the success and growth of the business.
“Rance Poehler is a highly accomplished business executive with a proven track-record for scaling businesses that are in a unique position to transform the industries they serve,” said Maccabe. “Rance brings the fortitude and execution prowess needed to transition the retail business to a full-fledged strategic partner for both customers and partners.”
Poehler joins Toshiba with extensive retail commerce solutions experience and insight. During his tenure as President of Panasonic Systems Communications Company of North America he led a $1.1 billion division morphing it from a product-centric organization to an end-to-end provider of innovative retail solutions in the areas of mobility, point-of-sale, digital signage, computer vision, and analytics that helped Fortune 1000 companies understand shopper demographics and behavior, improve associate engagement and create better customer experiences. While at Dell Technologies he served as vice president of worldwide sales for its cloud client computing team that represents a full suite of cloud and desktop virtualization solutions for retail that enabled scalable thin client solutions. Poehler’s experience also includes Pivot3 where he served as Chief Revenue Officer responsible for leading the global sales organization and executing on the company’s growth strategy and talent acquisition as they developed and went to market with a hyper-converged software platform that manages mixed workloads including IOT-surveillance, analytics, and hybrid cloud solutions.
“The retail industry is looking for new and innovative ways to adapt more quickly to customer needs while they optimize store operations and reduce the cost of delivering and managing their business. Toshiba has a strong worldwide retail position and is on the verge of disrupting the industry with their intelligent end-to-end solutions,” said Poehler. “I’m honored and excited about the opportunity to help this world-class retail commerce solutions business grow in ways that support our partner community, and helps our clients delight their customers while becoming even greater merchants.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for integrated in-store solutions. Together with a global team of dedicated business partners, we achieve brilliant commerce by advancing the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter, LinkedIn, Facebook and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005083/en/
Contact information
Fredrik Carlegren
Vice President of Marketing
(984) 444-2769
fcarlegren@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom